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Abstract
Background: The cause of neurodegeneration in progressive forms of multiple sclerosis is unknown.
We investigated the impact of specific neuroinflammatory markers on human neurons to identify
potential therapeutic targets for neuroprotection against chronic inflammation.
Methods: Surface immunocytochemistry directly visualized protease-activated receptor-1 (PAR1) and interleukin-1
(IL-1) receptors on neurons in human postmortem cortex in patients with and without neuroinflammatory lesions.
Viability of cultured neurons was determined after exposure to cerebrospinal fluid from patients with progressive
multiple sclerosis or purified granzyme B and IL-1β. Inhibitors of PAR1 activation and of PAR1-associated second
messenger signaling were used to elucidate a mechanism of neurotoxicity.
Results: Immunohistochemistry of human post-mortem brain tissue demonstrated cells expressing higher amounts
of PAR1 near and within subcortical lesions in patients with multiple sclerosis compared to control tissue.
Human cerebrospinal fluid samples containing granzyme B and IL-1β were toxic to human neuronal cultures.
Granzyme B was neurotoxic through activation of PAR1 and subsequently the phospholipase Cβ-IP3 second
messenger system. Inhibition of PAR1 or IP3 prevented granzyme B toxicity. IL-1β enhanced granzyme B-mediated
neurotoxicity by increasing PAR1 expression.
Conclusions: Neurons within the inflamed central nervous system are imperiled because they express more PAR1 and
are exposed to a neurotoxic combination of both granzyme B and IL-1β. The effects of these inflammatory mediators
may be a contributing factor in the progressive brain atrophy associated with neuroinflammatory diseases. Knowledge
of how exposure to IL-1β and granzyme B act synergistically to cause neuronal death yields potential novel
neuroprotective treatments for neuroinflammatory diseases.
Keywords: Neuroinflammation, Multiple sclerosis, Neurotoxicity, Protease-activated receptor, Granzyme B,
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Background
Multiple sclerosis (MS) is the most common disabling
neuroinflammatory disease of young adults [1]. The
pathophysiology of MS is not completely understood but
involves chronic inflammation within the central ner-
vous system [2] and progressive cerebral atrophy [3].
Symptomatic brain atrophy due to neurodegenera-
tion appears early in the course of MS [4] and is
progressive throughout the disease [5]. Grey matter
loss is correlated with the amount of demyelination
[6], but microscopically this atrophy is not associated
with the robust infiltrative immune response of de-
myelination and must occur by another mechanism
[7]. While the typical innate inflammatory process is
well-described, there has not been a translation of
this knowledge into effective treatments for the se-
quelae of neuroinflammatory diseases like MS. Given
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the significant association of neuronal loss with
many disabling and refractory MS symptoms, the ab-
sence of proven interventions that provide neuropro-
tection in a setting of chronic inflammation
represents a definite therapeutic gap.
A potential therapeutic target for neuroprotection
in MS would be antagonism of receptors activated
by cytotoxic substances released during inflamma-
tion. The protease-activated receptor (PAR) is a G-
protein coupled receptor whose unique activation
requires cleavage of an extracellular sequence by a
protease, a family of enzymes including many in-
flammatory mediators [8]. There are four known
PAR subtypes; all have been found on neurons
throughout the brains of several species [8]. The
PAR subtype designated “PAR1” was initially identi-
fied as the native receptor for thrombin [9], but it is
now known that neuronal PARs can be activated by
other proteases capable of cleavage within the extra-
cellular sequence, including granzyme B [10]. The
function of neuronal PAR1 appears varied. Neuronal
PARs are activated by proteases secreted by neurons
[11] and by proteases that breech the blood-brain
barrier [12]. During development, PAR1 activation is
necessary for neuronal process extension and sur-
vival [13, 14]. Neurons lacking PAR1 cannot exhibit
long-term potentiation [15]. In mature neurons,
PAR1 agonists are neurotoxic [16, 17]. Our labora-
tory has demonstrated that a single exposure to
granzyme B released by T lymphocytes is neurotoxic
through PAR1 activation [10, 18].
IL-1β upregulates neuronal PAR1 expression [16]. IL-
1β circulating within the cerebrospinal fluid (CSF) is a
biomarker of neuroinflammation caused by MS [19] and
subacute sclerosing panencephalitis [20]. IL-1β aug-
ments neuronal excitotoxicity [21]. Increased levels of
IL-1β in the CSF of patients with MS correlate with
greater cortical atrophy [22].
Prior in vitro investigations of granzymes and in-
terleukins in MS have examined single-dose expo-
sures, not chronic effects. In neuroinflammation,
significant elevations of IL-1β and granzyme B have
been documented within the CSF [18, 23], and
therefore, neurons in vivo reside within a milieu pro-
viding continuous exposure to these neurotoxic
entities.
In this study, we found that PAR1 is increased on
neurons’ surfaces within the brains and lesions of
patients with MS. Further, we demonstrated a unique
mechanism of how chronic PAR1 activation by gran-
zyme B is neurotoxic and determined that this spe-
cific mechanism could be driven by IL-1β. We
sought to expand the role of granzyme B in neuronal
death and provide a more thorough explanation of
how chronic PAR1 activation leads to neurotoxicity.




Histochemical portions of this study were performed
on formalin-fixed, paraffin-embedded archival mater-
ial of eight (n = 4 patients with MS, n = 4 control)
human brain autopsy tissue samples obtained from
The Human Brain and Spinal Fluid Resource Center,
University of California Los Angeles, CA. In the four
subjects designated with a diagnosis of MS, all pa-
tients had a chronic course. The four patients serv-
ing as controls in histochemistry experiments did
not have neurological diseases (Table 1).
For neurotoxicity and enzyme-linked immunosor-
bant assay studies, human CSF samples were
obtained via lumbar puncture from patients
diagnosed with secondary progressive MS (n = 7)
involved in a clinical trial of lamotrigine as de-
scribed previously [24, 25] or from NINDS patients
without neuroinflammation (n = 7) who served as
controls.
The Office of Human Subjects Protection and Re-
search at the National Institutes of Health approved this
research.
Neuronal cultures
iCell neurons (Cellular Dynamics International,
Madison, WI) which were derived from induced
pluripotent stem cells were used for the viability
and toxicity studies. Neurons were cultured accord-
ing to the manufacturer’s instructions. In brief, 96-
well plates were coated with 100 μl of 0.01% (w/v)
poly-L-ornithine (Sigma-Aldrich, St. Louis, MO) for
1 h at room temperature, washed twice with sterile
Table 1 Clinical and demographic features of patients included
in immunohistochemical studies





MS F 61 6.8 h Lung cancer
MS F 65 14.2 h Depression
MS F 46 13.0 h Cervical cancer
MS M 57 24.8 h Myocardial infarction
Control F 62 Unknown Otosclerosis
Control F 87 Unknown None
Control F 79 1.0 h Bronchiectasis, Torticollis
Control M 85 Unknown None
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distilled water, and finally coated with a 3.3-μg/mL
solution of laminin (Sigma-Aldrich) and molecular
biology-grade water. The dishes with laminin solu-
tion were incubated in a 37 °C incubator for at least
1 h prior to plating of neurons. The laminin solu-
tion was aspirated immediately before addition of
the cell suspension. A vial containing 2.5 million
iCell neurons was removed from liquid nitrogen
storage and immediately placed in a 37 °C water
bath for exactly 3 min. The cells were transferred to
a 50-ml conical tube and diluted to 10 ml total
volume with iCell Complete Maintenance Media
(Cellular Dynamics International) dropwise per man-
ufacturer’s protocol. Contents of the flask were
swirled gently throughout addition of media. Cell
viability was assessed from the initial volume and
then further dilution was performed to ensure that
sufficient quantity of cell suspension was added to
96-well plates to ensure at least 80,000 viable cells
were seeded per square centimeter. The cells were
kept in a 37 °C incubator in 5% (v/v) CO2. One day
after initial plating, there was a 100% exchange of
fresh iCell Complete Maintenance Media, and this
media was changed (50–75% exchange of the total
volume) every 1–2 days to ensure maximum viability
prior to experimental use. Neurons were not used
for experiments until at least 3 days after successful
plating. Opti-MEM reduced-serum media (Life Tech-
nologies, Carlsbad, CA) supplemented with 2% (v/v)
B27 (Life Technologies) served as the control and
treatment media for all cultures. For multiple day
experiments, there was a 100% replacement of media
and any additional components every 24 h until ana-
lysis. If an additive such as DMSO was used to pro-
mote solubility of a compound being evaluated, then
an equivalent amount of the additive was added to
control media daily. In experiments using human
CSF, the cultures were maintained in a 100-μl vol-
ume of undiluted thawed CSF from a single donor
with a 100% daily exchange to replenish CSF and
any additives such as protease inhibitors or
interleukin-1 (IL-1) receptor antagonist. Recombin-
ant human granzyme B, IL-1β, and thrombin as well
as agonists/antagonists of PAR1 and second messen-
ger components were obtained from R&D Systems/
Tocris Bioscience (Minneapolis, MN). Any agonists,
antagonists, or inhibitors were added at least 30 min
prior to addition of granzyme B and IL-1β. Atopaxar
(E5555) was prepared using a variant of the conver-
gent synthesis described in the patent # US 2006/
0058370 A1 [26]. The coupling of a fluorinated
cyclic benzamidine (A) with a morpholine-
substituted phenacyl bromide (B) in THF gave the
HBr salt of Atopaxar as seen below.
The syntheses of (A) and (B) are shown in the follow-
ing Schemes 1 and 2.
Starting with 3-fluorocatechol, the synthesis required
essentially seven steps. Benzamidine (A) was ultimately
prepared from phthalimide (2) which could be prepared
from bromide (1).
Starting with 2-tert-butylphenol, the synthesis of (B)
required essentially six steps. One slight variation from
the Eisai patent procedure involved the hydrolysis of
ketal (3) back to the methyl ketone (4). This material
could be purified chromatographically before brominat-
ing, resulting in much cleaner phenacyl bromide (B).
Atopaxar hydrobromide prepared in this manner gave
satisfactory NMR, elemental analysis, and liquid chro-
matography/mass spectroscopy. The crystal retained
0.25 equivalent of THF as seen by nuclear magnetic res-
onance and elemental analysis.
Immunohistochemistry
Sections of 100-μm thickness were prepared from
formalin-fixed and paraffin-embedded brain sections
from control and from subcortical white matter contain-
ing known lesions in patients with MS. They were
deparaffinized using standard protocols. Antigen re-
trieval was performed using sodium citrate buffer
(10 mM sodium citrate, 0.05% (v/v) Tween 20).
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Endogenous peroxidase was inhibited using a dual en-
zyme block solution (Dako, Carpinteria, CA) and native
protein block was achieved with a serum-free protein
block solution (Dako). Following a TBS-Tris wash, sec-
tions were immunolabeled for 1 h at room temperature
using mouse monoclonal anti-PAR1 (1:500, Abcam, San
Francisco, CA) or rabbit polyclonal anti-IL1 receptor
(1:100, Abcam) as primary antibodies. After a wash with
TBS-Tris, sections were incubated with a Powervision
poly-HRP anti-rabbit or anti-mouse secondary antibody
solution (Dako). Development for visualization of anti-
body binding within the tissue was achieved using the
chromagen 3,3'-diaminobenzidine (Sigma). Hematoxylin
(10%; w/v) was used to provide a counterstain.
Scheme 1 Synthesis of florinated cyclic benzamidine
Scheme 2 Synthesis of morpholine-substituted phenacyl bromide
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Omissions of the primary or secondary antibodies were
used as negative controls.
Quantification of immunohistochemistry
The total number of cells and immunolabeled cells were
counted manually in a minimum of ten fields from
within and immediately around subcortical white matter
(healthy or containing a lesion) and the adjacent cerebral
cortex (layer VI) of patients with MS and controls.
Lesions were defined based on demyelination borders
identified with Luxol Fast Blue staining of an adjacent
section. For quantification of cell number within a tissue
section, a 20-μm grid was aligned manually across the
desired counting area and all cells fully within the sec-
tion were counted using a microscope with a 20× object-
ive configured to image in transmitted light mode.
Optimal light and focal settings were established prior to
counting. Serial sections stained with anti-NeuN anti-
body (1:1000, Abcam) were used to definitively identify
whether a given counted cell nucleus belonged to a
neuron. Cells were graded as “no,” “low”, or “high” ex-
pression based on comparative visual appearance.
Regions with significant tissue artifacts or overlapping
with a tissue edge were excluded from analysis. The total
density of cells was estimated from the observed counts
using a modified Abercrombie estimation [27] and is
expressed as a calculated density (neurons/mm2).
Enzyme-linked immunosorbent assay
Concentrations of granzyme B (eBioscience, San Diego,
CA) and IL-1β (Abcam) were quantitated in CSF sam-
ples using enzyme-linked immunosorbent assay (ELISA)
kits according to manufacturer’s instructions. CSF sam-
ples from patients with MS or control patients were in-
cubated on microtiter strips with biotinylated
monoclonal anti-granzyme B or IL-1β antibody.
Streptavidin-peroxidase and substrate were added, and
absorbance was measured at 450 nm. Quantitation of se-
creted granzyme B and IL-1β were determined based on
a standard curve generated from known standards in-
cluded in the kits.
Other CSF assays
Total protein concentration in CSF samples was ana-
lyzed using a BCA Protein Assay (Life Technologies)
following the manufacturer’s instructions. Glucose con-
centration was estimated in CSF using a Glucose Colori-
metric Assay Kit (Cayman Chemical, Ann Arbor, MI). A
glutamate assay kit (Abcam) was used to measure CSF
glutamate concentrations.
Neuronal viability and toxicity
The MultiTox-Fluor Multiplex Cytotoxicity Assay
(Promega, Madison, WI) was used for simultaneous
evaluation of viability and toxicity in neuronal cul-
tures for all conditions. Cultures were maintained in
96-well plates with black walls in a total volume of
100 μl of media with or without experimental addi-
tives such as granzyme B, IL-1β, or inhibitors. To in-
hibit granzyme B activity in CSF samples, these
samples were pretreated with the selective cell-
permeable protease inhibitor Z-Ala-Ala-Asp-chloro-
methylketone (Enzo Life Sciences, Farmingdale, NY).
The optimal concentration for additives was deter-
mined empirically. The MultiTox-Fluor Multiplex
Cytotoxicity Assay Reagent was prepared at two times
concentration according to the manufacturer’s instruc-
tions and 100 μl of this assay reagent was added to
each well. Each well’s contents were mixed by gentle
pipetting. The plates were returned to the incubator
for 1 h. Fluorescence intensity was then measured
using a FlexStation 3 Microplate Reader and SoftMax
Pro software (Sunnyvale, CA) with the following set-
tings, for viability: excitation = 400 nm and emission =
505 nm and for toxicity: excitation = 485 nm and
emission = 520 nm. All conditions were performed at
least in duplicate and data were pooled from multiple
independent experiments. For multiple day cumulative
toxicity measurements, several wells were analyzed at
each daily time point to generate a cumulative tox-
icity percentage for a given day. Data were collected
as relative fluorescence units. Conditions included in
each experiment included empty wells as well as wells
without neurons containing just media and additives
for background assessment, wells containing neurons
in experimental media with appropriate additives
which served as negative controls, and wells with suf-
ficient saponin 0.1% (w/v) added prior to assessment
to ensure 100% toxicity which served as the positive
control condition for toxicity calculation purposes.
Immunocytochemistry
Neurons were fixed in 4% (w/v) paraformaldehyde for
10 min at room temperature, followed by three
washes with PBS. After incubation in 0.1% (v/v) Tri-
ton X-100 in PBS (PBS-T) for 10 min at room
temperature, the cells were incubated with blocking
buffer (PBS-T containing 4% (v/v) goat serum and 1% (v/
v) glycerol (Sigma-Aldrich) at room temperature for
20 min. Cells were immunostained with mouse monoclo-
nal anti-PAR1 (1:500, Abcam) and rabbit polyclonal anti-
IL1 receptor (1:100 Abcam), followed by corresponding
secondary antibodies (anti-mouse Alexa Fluor 488 1:200
Abcam, anti-rabbit Alexa Fluor 647 1:200 Abcam) and
4′,6-diamidino-2-phenylindole (DAPI) nuclear staining.
Images were acquired on a Zeiss LSM 510 META multi-
photon confocal system (Carl Zeiss, Dublin, CA) or an
EVOS fluorescence microscope (AMG, Bothell, WA).
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Immunocytochemistry quantification
The total number of DAPI-stained nuclei per field pro-
vided an estimate of the total number of neurons
present. Degenerating nuclei were excluded from counts
as were indistinct DAPI-positive structures. The number
of PAR1-positive neurons was then counted after over-
laying these images on the DAPI-positive images. Only
neurons with distinct DAPI-positive nuclei were noted
for analysis. The percentage of positive neurons for a
given field was generated by dividing the number of
PAR-stained neurons by the total of the counted DAPI-
positive nuclei.
Real-time quantitative polymerase chain reaction
PAR1 expression was determined by quantitative real-
time polymerase chain reaction (qPCR) as described
elsewhere [28]. Briefly, cultured iCell neurons were
treated with granzyme B, interleukin 1β, and/or siRNA
designed to suppress PAR1 for the stated times and total
RNA was extracted using a Qiagen RNeasy mini kit
(Qiagen, Valencia, CA). The RNA samples were treated
with DNase I (Invitrogen, Grand Island, NY) for 15 min
followed by Turbo DNAse treatment (Life Technologies)
according to the manufacturer’s instructions for “strin-
gent” conditions. Then complementary DNA (cDNA)
was synthesized from this purified total RNA using ran-
dom primers (PAR1 sense: 5′-AGTAGGCTATTCCTG
AGAGCTGCAT-3′; PAR1 antisense: 5′-ATGGCCCTG
GCATGTGTCT-3′) and SuperScript III First-Strand
cDNA kit (Invitrogen). The resulting cDNA was then
mixed with gene-specific primers and SYBR Green PCR
universal master mix (Life Technologies). RNA was
amplified using an ABI Prism 7000 Sequence Detection
System (Applied Biosystems, Foster City, CA) according
to the manufacturer’s instructions. The relative levels of
messenger RNA (mRNA) were calculated using the
ΔΔCt method by normalization to an internal control,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
siRNA
The Accell siRNA kit (Thermo Scientific, Waltham,
MA) was used to reduce expression of PAR1. A pooled
set of siRNA sequences, three directed against the hu-
man F2R (thrombin receptor, PAR1) Open Reading
Frame and one against the 3′UTR of the gene were
used. The siRNA introduction was performed according
to the manufacturer’s instructions for “plated cells sensi-
tive to media-free delivery conditions.” To maximize
siRNA delivery to neurons, an aliquot of TransIT-X2
Dynamic Delivery System (Mirus Bio, Madison, WI) was
added with the diluted siRNA to the Accell delivery buf-
fer. After 72 h, the siRNA solution was replaced with ex-
perimental media following a wash with PBS. Reduction
in PAR1 protein was confirmed by a Western blot
analysis using anti-PAR1 antibody (1:1000) following a
methodology otherwise as described elsewhere [18].
Statistics
Statistical analyses were performed using Graphpad
Prism (La Jolla, CA) software (version 6.05). For toxicity
and viability measures, raw data were compiled into per-
centage of the controls used in their respective experi-
ments. Data are presented as mean ± standard error of
the mean. Data analysis included an analysis of variance
(ANOVA; one-way, two-way, or repeated measures as
indicated) with a post hoc test to correct for multiple
comparisons as noted, a Tukey test was used when com-
parisons of all means were made to one another, a
Dunnett test was used for comparisons of means to a
single appropriate control condition. Correlations were
used to generate Pearson statistics where indicated. Stat-
istical significance was established as a p value <0.05.
Results
PAR1 surface expression is increased in brain tissue from
patients with MS
Human post-mortem brain tissue sections from patients
with MS and control patients lacking neuroinflammatory
disease were used to investigate whether there were
qualitative or quantitative differences in neurons ex-
pressing PAR1 and the IL-1 receptor within healthy and
inflammatory subcortical tissue samples.
Brain tissue from both control patients and patients
with MS exhibited PAR1 staining; neurons and glia had
detectable surface expression of PAR1 (Fig. 1a, b). IL-1
receptor staining was consistently rated as “low” or “no”
expression without visual distinction between tissue
from patients with MS or control patients (Fig 1c, d).
Brain tissue originating from patients with MS had sig-
nificantly fewer neurons overall owing to loss of cellular-
ity within white matter lesions and in the cortex
(Table 2). Despite the discrepancy in numbers of cells,
there were approximately 30% more PAR1 high expres-
sion neurons within the cortex adjacent to, inside, and
around lesions from brain tissue samples of patients
with MS compared to healthy patients’ tissue. Regions
around and within demyelinated lesions had concentra-
tions of “high expression” rated cells (Fig. 1e). Addition-
ally, there were prominent PAR1-positive neurons with
darkly stained axons situated inside demyelinating le-
sions (Fig. 1f ); similar neurons were not found in healthy
control samples. Omitting the primary antibodies from
the staining protocol yielded no visible PAR1 or IL-1 re-
ceptor staining in brain tissues (not shown).
Inflammatory CSF is neurotoxic via granzyme B
We used ELISA kits to determine the levels of granzyme
B and IL-1β within samples of human CSF to confirm
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the relative amounts of granzyme B and IL-1β in CSF
samples from patients with MS. Granzyme B levels in
CSF from patients with MS ranged from 10.11 to
12.22 pg/ml (mean = 14.22 pg/ml), and the IL-1β levels
were detectable at values between 7.30 and 24.56 pg/ml
(mean = 17.38 pg/ml). There was a significant positive
correlation between granzyme B and IL-1β within CSF
samples from patients with MS (r = 0.852, p < 0.015). In
control samples, the granzyme B levels were near the as-
say’s detection threshold (range <0.20–1.10 pg/ml) and
Fig. 1 PAR1 and IL-1 receptor surface expression in human brain tissue. a Immunohistochemistry for PAR1 demonstrates a low level of baseline
staining in healthy human brain tissue. b There is more prominent PAR1 staining within MS brain tissue. c IL-1 receptor staining in healthy tissue
and d around a demyelinated plaque were similar. e Luxol fast blue stain shows a demyelinated region and subsequent images show PAR1
staining is pronounced within a lesion’s borders and follows a gradient diminishing at approach to the lesion’s outermost border. f Within
demyelinated lesions there are darkly stained PAR1-positive neurons with visible unmyelinated axons (arrows). Bars = 50 μm
Table 2 Neuronal density in brain tissue from patients with MS or control patients
Density (neurons/mm2) Control cortex MS cortex MS lesion Significance
Total number 65.3 ± 3.9 55.6 ± 2.1* 46.6 ± 8.2** *p < 0.01, ** p < 0.001
PAR1 high expression 29.0 ± 4.2 37.7 ± 2.8* 44.3 ± 6.8* *p < 0.01
IL-1 receptor low expression 58.9 ± 1.1 59.2 ± 1.3 58.1 ± 1.4 NS
Data are mean ± standard error of the mean
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IL-1β levels in CSF samples from control patients were
below the assay’s detection threshold (<6.5 pg/ml).
To assess whether CSF from patients with MS was
neurotoxic, aliquots of the assayed CSF samples were then
introduced into human neuron cultures derived from in-
duced pluripotent stem cells for 3 days. Viability and tox-
icity were measured simultaneously within each sample
well at the end of the third day. Following 3 days of CSF
exposure, there was significant neurotoxicity (>70%) in
cultures cultured with CSF from patients with MS com-
pared with neurons in control media (Fig. 2a, b). When
viability and toxicity were analyzed for the samples, there
was a significant negative correlation (r2 = 0.882, p <
0.002) between the concentration of granzyme B within
the sample well and the viability of the neurons within the
well after 3 days (Fig. 2c). A reciprocal significant positive
correlation (r2 = 0.853, p < 0.0004) between granzyme B
concentration and toxicity was also observed (Fig. 2c).
The correlations between IL-1β concentration and toxicity
(r2 = 0.5759, p < 0.01) and viability (r2 = 0.5932, p < 0.009)
were significant but less robust. The control patients’ CSF
was as non-toxic to the neuronal culture as the control
neuronal media (Fig. 2d). There was no difference be-
tween the CSF samples from patients with MS and control
CSF with respect to concentrations of glucose, total pro-
tein, or L-glutamate (Table 3).
When CSF from patients with MS was pretreated with a
granzyme B-specific protease inhibitor prior to being added
into neuronal cultures, the observed neurotoxicity was re-
duced and not significantly different than control media
with protease inhibitor. Addition of a selective IL-1 recep-
tor antagonist (AF 12198) decreased toxicity by approxi-
mately 50%. Protease inhibition together with IL-1 receptor
antagonism was as effective as protease inhibition alone in
preventing neurotoxicity after 3 days of exposure (Fig. 2d).
Granzyme B and IL-1β act together to diminish neuronal
viability
To determine the effect of repeated chronic exposure of
granzyme B on neurons, human neurons were plated at a
Fig. 2 Effects of cerebrospinal fluid (CSF) samples from patients with MS on human neuronal cultures. Cortical neurons derived from induced
pluripotent stem cells were treated with undiluted human CSF from patients with MS or from patients without neuroinflammatory diseases for
3 days. a Neuron cultures maintained in CSF from control patients verified to have low levels of granzyme B and interleukin-1β had no evidence
of injury or toxicity. b Neuron cultures exposed to CSF from patients with MS were fewer in number and had morphological evidence of damage
(i.e., shorter axons, simplified arborization). c The toxicity induced by CSF from patients with MS was directly related to the CSF’s granzyme B
content. Conversely, neuronal viability diminished with increasing concentration of granzyme B within a given sample. Data are shown as the
mean from duplicate experiments. d The neurotoxicity of CSF from patients with MS was significantly greater at 3 days than CSF from control
patients and could be abolished by the cell-permeable granzyme B inhibitor Z-Ala-Ala-Asp-chloromethylketone (25 μM) and partially
prevented by inhibition of the interleukin-1 receptor using the antagonist AF 12198 (1 μM). A mixture of granzyme B inhibitor and AF
12198 was no more effective than the granzyme B inhibitor alone at preventing cumulative neurotoxicity. ****p < 0.0001 relative to CSF
from control patients, ####p < 0.001 relative to CSF from patients with MS, one-way ANOVA with post hoc Tukey’s test, n = 7 per condition. Data are
shown as the mean ± standard error of the mean from duplicate experiments
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known, fixed concentration and allowed to mature per
manufacturer’s guidelines. Once neurons exhibited a ma-
ture phenotype, they were exposed to a range of concen-
trations of granzyme B for 7 days. To maintain potency
throughout the duration of the experiments, granzyme B
was replenished on a daily basis for 7 days with neuronal
viability measured in a set of neurons reared in parallel at
each 24-h time point. As in previous studies, a single 24-h
exposure to granzyme B yielded a dose-dependent reduc-
tion in viability (Fig. 3a). However, when granzyme B was
replenished on a daily basis, the effect of granzyme B in
culture reached a plateau (Fig. 3b). By day 4, the granzyme
B toxicity approached zero, and the toxicity converged on
that of the control conditions and subsequent days’
Table 3 Cerebrospinal fluid parameters
Control Multiple sclerosis Significance
Glucose (mg/dl) 75.43 ± 7.50 73.14 ± 7.12 NS
Total protein (mg/dl) 19.86 ± 2.30 20.57 ± 3.84 NS
Glutamate (μg/l) 0.28 ± 0.11 0.21 ± 0.04 NS
Granzyme B (pg/ml) 0.05 ± 0.02 14.22 ± 1.49 p < 0.05
Interleukin-1β (pg/ml) <6.5 17.38 ± 2.17 p < 0.05
Data are mean ± standard error of the mean
Fig. 3 Granzyme B-mediated neurotoxicity. a Pure cortical neuron cultures were treated with granzyme B and the viability and toxicity were
measured simultaneously. A single, 24-h exposure to granzyme B at escalating concentrations (4, 8, and 10 nM) replicated a dose-dependent
decrease in neuron viability. The 8- and 10-nM doses caused significantly decreased viability relative to control media. **p < 0.01 and ***p < 0.001,
respectively, one-way ANOVA with post hoc Dunnett test, n = 8 per condition. Data are shown as the mean ± standard error of the mean from
four separate experiments. b When granzyme B was added for five consecutive days, the viability of the all cultures stabilized at day 3. **p < 0.01,
***p < 0.001 and ****p < 0.0001 relative to control media, repeated measures ANOVA with post hoc Dunnett test, n = 10 per condition. Data are
shown as the mean ± standard error of the mean from three separate experiments. c Granzyme B-mediated toxicity peaked on day 2 of exposure
followed by a decline to control toxicity levels on day 4. ***p < 0.001 and ****p < 0.0001 relative to control media, repeated measures ANOVA post
hoc Dunnett test, n = 10 per condition. Data are shown as the mean ± standard error of the mean from three separate experiments
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exposures were not toxic relative to control media (Fig. 3c).
The decline in viability noted on day 5 in culture was uni-
versal and is an expected outcome from depriving these
neurons of proprietary media’s nutrients.
To investigate the basis for the observed stabilization
in viability and toxicity, immunocytochemistry tech-
niques were used to visualize the PAR1 receptor on the
surface of cultured neurons, and we observed that con-
sistently the overwhelming majority of neurons (91.66 ±
4.09%) in this specific neuron preparation had visible
surface expression of PAR1 at baseline (Fig. 4a). Follow-
ing several days of granzyme B exposure when toxicity
returned to control media equivalence, we observed that
the percentage of PAR1-positive neurons would sequen-
tially decline to less than 10% (6.57 ± 0.64%) of the total
number (Fig. 4b). The expression of IL-1 receptor in-
creased after initial granzyme B exposure then remained
stable for the duration of exposure (Fig. 4c, d). The tim-
ing of the decline in the percentage of PAR1-positive
neurons in these cultures mirrors the fall in toxicity we
observed with repeated presentation of granzyme B
(Fig. 4e). Thus, it appeared that a finite number of neu-
rons expressing PAR1 were at-risk to granzyme B and
the ultimate total toxicity achieved corresponded to neu-
rons expressing high levels of PAR1 on their surfaces.
We explored the role of neuronal surface PAR1 in
granzyme B neurotoxicity PAR1 by both increasing and
decreasing PAR1 expression. IL-1β increases PAR1 ex-
pression on neurons, and administering IL-1β with gran-
zyme B had a dramatic effect on neurotoxicity by
Fig. 4 PAR1 and IL-1 receptor surface expression on cultured neurons. a At baseline on day 0, most neurons showed surface expression of PAR1
by immunocytochemistry visualized here using a green fluorescent secondary antibody (bottom left panels). A red fluorescent antibody was used
to visualize IL-1 receptor (top left panels), and IL-1 receptor surface expression was noted on all neurons and was not significantly changed during
granzyme B exposure. Nuclei were stained with DAPI (blue) and superimposed onto the combined image (lower right panels). b The percentage
of neurons with PAR1 surface expression visible by fluorescence significantly decreased over the course of 5 days of chronic exposure to granzyme B
and IL-1β relative to the total number of DAPI-stained nuclei at any given time ****p < 0.0001 relative to control media, repeated measures ANOVA
with post hoc Dunnett test, n = 8 per condition. Data are shown as mean ± standard error of the mean from four separate experiments. c On days 1, 3,
and 5 in media containing granzyme B (10 nM), there was a reduction in the number of neurons in culture evident at all time points and a morpho-
logical changes consistent with chronic injury including shortened axons. d After 1, 3, and 5 days in media containing granzyme B (10 nM) and IL-1β
(20 ng/ml), the total number of neurons in culture, and the number of neurons staining positive for PAR1 were both significantly reduced
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sustaining neural losses throughout the 5-day observa-
tion such that the cumulative loss of neurons by day 5
reached approximately 100% (Fig. 5a). The increased
toxicity was not due to a direct toxic effect of IL-1β be-
cause IL-1β was not toxic when administered alone
(Fig. 5b). We introduced a selective antagonist of the IL-
1 type I receptor (AF12198) to block IL-1β signaling.
The antagonist blocked the IL-1β component of gran-
zyme B toxicity (Fig. 5b). IL-1β acting at the IL-1 recep-
tor altered PAR1 production in the neurons. IL-1β
caused PAR1 mRNA expression to increase twofold and
PAR1 protein to increase fourfold (Fig. 5c). Antagonism
of IL-1 receptors prevented a significant IL-1β-mediated
increase in PAR1 mRNA and protein.
We used a siRNA preparation to reduce PAR1 expres-
sion in vitro. A siRNA cocktail directed against PAR1
mRNA markedly reduced PAR1 mRNA and protein;
these results were confirmed by real-time qPCR and
Western blot analysis (Fig. 5d). Inhibiting PAR1 using
siRNA made neurons resistant to granzyme B toxicity.
When neurons with inhibited PAR1 expression were
chronically exposed to granzyme B, there was no de-
crease in viability (Fig. 5e). A scrambled siRNA sequence
of PAR1 and siRNA for a housekeeping gene (GAPDH)
both failed to prevent granzyme B toxicity (Fig. 5e).
PAR1 activation mediates granzyme B neurotoxicity
To establish PAR1 as the definitive receptor for the
granzyme B-mediated neurotoxicity, two different strat-
egies were attempted, antagonism and the use of alterna-
tive PAR agonists. To determine if direct antagonism of
PAR1 could prevent neurotoxicity due to granzyme B,
an antagonist compound specific to PAR1, Atopaxar
(also known as “E5555”), was placed into the media prior
to the introduction and replacement of granzyme B.
Atopaxar successfully prevented chronic neurotoxicity
due to granzyme B in a dose-dependent fashion
(Fig. 6a).
To determine if maximum activation of PAR1 had
been achieved at the selected dose of granzyme B
(10 nM), we added the native ligand for the PAR1 recep-
tor, thrombin, with granzyme B and observed toxicity
over the course of 3 days. Thrombin alone was neuro-
toxic but produced no additional toxicity after pre-
treatment with granzyme B (Fig. 6b). As an additional
confirmation, the peptide ligand TFLLR-NH2, a non-
protease agonist of PAR1 receptors, was added with and
without granzyme B. This selective agonist proved as
toxic as granzyme B when introduced alone, but the in-
active reverse sequence of this peptide (RLLFT-NH2) did
not have any toxic effect (Fig. 6c). When TFLLR-NH2
was added with granzyme B, as was the case with throm-
bin, there was no additional significant increase in tox-
icity. Therefore, we concluded that the observed toxicity
was attributable only to optimized activation of PAR1
and not significantly influenced by off-target effects.
Inhibition of second messenger systems
Protease activation of PAR1 can trigger several different
second messenger entities including phospholipase Cβ,
IP3, PI-3-kinase, protein kinase C, and ERK 1/2. We
screened several second messenger inhibitors directed
against targets within these pathways to investigate
whether interference with a specific path could modify
the toxicity of chronic granzyme B exposure.
We found that blocking phospholipase Cβ hydrolysis
of PIP2, an intermediate in the IP3/diacyl glycerol path-
way, using the inhibitor U73122 prevented chronic gran-
zyme B-mediated neurotoxicity (Fig. 7a). Inhibition
using U73122 had no significant impact on acute gran-
zyme B toxicity as its effect was significant over a time
course of several days and evident only when cumulative
toxicity was analyzed (Fig. 7c).
The hydrolysis of PIP2 catalyzes the production of in-
ositol trisphosphate (IP3). Two inhibitors of IP3, 2-APB
and (−)-xestospongin C, prevented neurotoxicity due to
chronic granzyme B (Fig. 7b). The coupling of PAR1 ac-
tivation through IP3 production completes a clear and
known mechanism of neurotoxicity (Fig. 7d). We inci-
dentally observed a dose-dependent improvement in via-
bility following an acute granzyme B toxicity for 2-APB
exclusively (Fig. 7c).
Pre-treatment with inhibitors targeting protein kinase
C (Ro 32–0432 hydrochloride), PI3 (LY 294002), ERK
(FR180204), and src kinase (Src Inhibitor-1) had no ef-
fect on granzyme B neurotoxicity (Fig. 8a). Minocycline,
a known neuroprotective agent, provided a mild reduc-
tion in neuronal death due to chronic granzyme B
(Fig. 8b).
Discussion
Chronic granzyme B exposure is neurotoxic because of
PAR1 activation. The neurotoxicity mechanism attrib-
uted to granzyme B in these experiments occurs via
maximal activation of PAR1 on the neuronal surface be-
cause adding additional PAR1 agonists to granzyme B
did not significantly increase toxicity. Previous research
has demonstrated that CSF from patients with MS is dir-
ectly toxic to cultured rat neurons [29]. The CSF of pa-
tients with MS contains abundant granzyme B [18] and
IL-1β [19, 30], and CSF IL-1β concentrations correlate
with MS-associated brain atrophy [22]. Our research
shows that persistent granzyme B drives neurotoxicity
and IL-1β augments neuronal death by increasing PAR1
expression. Therefore, the implication of this research is
clear: the coincidence of granzyme B and IL-1β within
the central nervous systems of patients with neuroin-
flammation is likely to cause and accelerate neuronal
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Fig. 5 Enhancement of granzyme B toxicity with IL-1β. a IL-1β (20 ng/ml) augments granzyme B neurotoxicity. Cumulative neurotoxicity of
combined granzyme B and IL-1β reaches 100%. ****p < 0.0001 cumulative toxicity relative to control media, ####p < 0.0001 cumulative toxicity
relative to granzyme B + IL-1β (two-way ANOVA with post hoc Tukey’s test, n = 5/condition. Data are mean ± standard error of the mean from
three separate experiments). b IL-1β is not toxic by itself. The IL-1 receptor antagonist AF 12198 (1 μM) abolished IL-1β effect after 3 days of
co-culture with granzyme B and IL-1β (20 ng/ml). ****p < 0.0001 relative to control media, ####p < 0.0001 between granzyme B + IL-1β and
granzyme B+ IL-1β + IL-1 receptor antagonist, repeated measures ANOVA with post hoc Tukey’s test, n = 6/condition. Data are mean ± standard
error of the mean from three separate experiments. c After 3 days of exposure, IL-1β (20 ng/ml) significantly increased PAR1 mRNA as shown by
qPCR and PAR1 protein relative to control levels using Western blot analysis. The IL-1 receptor antagonist AF 12198 (1 μM) blocked the IL-1β
effect on PAR1 mRNA and protein. A pooled PAR1 siRNA preparation reduced PAR1 mRNA and protein below control conditions. d Western
blot analysis (below bar graph) confirmed the relative amounts of PAR1 protein in respective conditions. *p < 0.05, ****p < 0.0001 relative to control
media, one-way ANOVA with post hoc Tukey’s test, n = 4/condition. Data are mean ± standard error of the mean from duplicate experiments.
e Granzyme B had no toxicity when PAR1 siRNA reduced PAR1 protein levels. A pooled PAR1 siRNA preparation inhibited all granzyme B neurotoxicity;
IL-1β had no effect. Two control siRNA, anti-GAPDH, and a scrambled PAR1 sequence had no effect. ****p < 0.0001 relative to control
media, ####p < 0.0001 between PAR1 siRNA + granzyme B+ IL-1β and other siRNA as noted, one-way ANOVA with post hoc Tukey’s test,
n = 8/condition. Data are mean ± standard error of the mean from four separate experiments
Lee et al. Journal of Neuroinflammation  (2017) 14:131 Page 12 of 18
loss. Our finding of reduced total numbers of neurons in
brains from patients with MS corroborates prior pub-
lished immunohistochemistry studies showing the same
[31]. The demonstration in this work of PAR1-positive
neurons prominently within demyelinated lesions is like-
wise in keeping with prior reports [32] and confirms that
neurons situated within inflamed tissues possess the ne-
cessary receptor for granzyme B to activate and are
therefore at high risk of loss. It is worth noting that the
traditional cytotoxicity of granzyme B is dependent upon
co-release of perforin, but perforin-independent neuro-
toxicity is well-established, and furthermore, this re-
search does not contradict our previous finding of PAR1
cleavage causing downstream activation of the potassium
channel Kv1.3 [10, 18]. The observation of IP3 inhibition
interfering with acute exposure granzyme B toxicity is
likely attributable to a known effect of 2-APB on the
Kv1.3 receptor [18].
PAR1 activation by granzyme B can lead to signaling
through multiple second messenger pathways. Our re-
search shows activation of the phospholipase-Cβ and
PIP2-IP3 pathway is critical to chronic PAR1 neurotox-
icity. Phospholipase-Cβ and IP3 have established links to
neuroinflammation. An unbiased genome-wide associ-
ation studies identified a linkage of phospholipase C iso-
forms to the pathophysiology of MS [33]. IP3
Fig. 6 Effects of PAR1 antagonism and agonism. a Atopaxar, a selective antagonist of PAR1 significantly reduced granzyme B total cumulative
toxicity at 500 nM, 1 μM, and 10 μM pre-treatment doses after 5 days of co-incubation with granzyme B and IL-1β. The cumulative toxicity at the
1 μM dose of Atopaxar was not significantly different from toxicity of control media, which contained the same concentration of DMSO necessary
to solubilize Atopaxar, nor was Atopaxar itself significantly more toxic than control media. *p < 0.05, ****p < 0.0001 relative to control media,
####p < 0.0001 relative to granzyme B+ IL-1β, repeated measures ANOVA with post hoc Tukey’s test, n = 8 per condition. Data are shown as the
mean ± standard error of the mean from five separate experiments. b Thrombin (500 nM), an agonist of PAR1, causes mild neurotoxicity when
added to neuronal cultures for 3 days. When granzyme B is added with thrombin, there is no additive toxic effect. *p < 0.05, ****p < 0.0001 relative
to control media, one-way ANOVA with post hoc Tukey’s test, n = 10 per condition. Data are shown as the mean ± standard error of the mean
from duplicate experiments. c The peptide activating sequence TFLLR (5 μM), an agonist of PAR1, reduced neuronal viability after 3 days to the
same extent as 10 nM granzyme B. When granzyme B and TFLLR were combined, there was no additional increase in toxicity. RLLFT, the inverse
peptide of the agonist sequence, was non-toxic by itself and did not increase toxicity when paired with granzyme B. ****p < 0.0001 relative to
control media, one-way ANOVA with post hoc Tukey’s test, n = 10 per condition. Data are shown as the mean ± standard error of the mean from
three separate experiments
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production is increased in neurons at several time points
after inoculation against myelin-derived products in the
experimental autoimmune encephalitis model of MS
suggesting IP3 dysregulation is an early and persistent
event in central nervous system inflammation [34]. IP3
is the critical mediator of brain vascular epithelial cell
inflammatory response caused by arachidonic acid [35].
Therefore, IP3 is a key player in neuroinflammation, and
our work phosopholipase-Cβ and IP3 are significant tar-
gets for protecting neurons and glia from toxicity within
an inflammatory milieu.
Knowledge of this novel pathological process suggests
potential therapeutic considerations. PAR1 contributes
to post-stroke neurotoxicity [36], and PAR1 activation
causes oligodendrocyte death [37], yet despite experi-
mental data demonstrating thrombin as a neurotoxic
agent [38], no trial to date has examined anti-thrombin
receptor therapy as a potential treatment for
neuroinflammatory-associated neurodegeneration. Sev-
eral publications have demonstrated that aspirin, an
agent that interferes with thrombin (the native agonist
of PAR1) reduces fatigue in patients with MS [39, 40].
While the precise mechanism of how aspirin ameliorates
MS-related fatigue is not known, the effect is independ-
ent of lowering basal body temperature [40] and may be
the result of inhibiting IL-1β release. Irreversibly inhibit-
ing thrombin using aspirin would also indirectly de-
crease PAR1 signaling by decreasing thrombin activity.
Activation of the PAR family of receptors on endothelial
cells is a major factor in promoting a local inflammatory
response that includes cytokine release [41], and PAR in-
hibitors therefore might be a therapy with manifold
Fig. 7 Inhibition of protein kinase C and IP3 reduced neurotoxicity. a Pre-treatment with the phospholipase C inhibitor U73122 for 30 min significantly
reduced neurotoxicity caused by 3 days of exposure to granzyme B (10 nM) and IL-1β (20 ng/ml). All doses of U73122 were effective at reducing
toxicity relative to maximum IL-1β augmented granzyme B-mediated toxicity. The 1 and 10 μM doses reduced toxicity to levels identical to that of
control media. ***p < 0.001, ****p < 0.0001 relative to control media with 10% ethanol (vehicle), ####p < 0.0001 relative to granzyme B + IL-1β condition,
one-way ANOVA with post hoc Tukey’s test, n = 5 per condition. Data are shown as the mean ± standard error of the mean from five
separate experiments. b Several doses of the selective IP3 inhibitors 2-APB and xestospongin significantly reduced the cumulative toxicity
typically seen after 3 days. *p < 0.05, ****p < 0.0001 relative to control media and ##p < 0.01, ####p < 0.0001 relative to granzyme B + IL-1β,
one-way ANOVA with post hoc Tukey’s test, n = 5 per condition. Data are shown as the mean ± standard error of the mean from four
separate experiments. c Neuronal viability was preserved in an acute, single day exposure to 10 nM granzyme B following pre-treatment
with only 100 μM 2-APB, ****p < 0.0001 relative to control media, ####p < 0.0001 relative to granzyme B + IL-1β, one-way ANOVA with post
hoc Tukey’s test, n = 5 per condition. Data are shown as the mean ± standard error of the mean from duplicate experiments. d Proposed
mechanism of action for granzyme B-mediated neurotoxicity with IL-1β assistance. IL-1β promotes increased numbers of PAR1 receptors
on neuronal membrane surface. Granzyme B cleaves the PAR1 receptors’ extracellular domains. Activated PAR1 directly couples with
phospholipase Cβ which in turn yields increased IP3 production and leads to the well-described cellular processes that compromise
mitochondrial function and eventually culminate in neuronal demise
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clinical benefits in neuroinflammatory diseases. The
PAR1 antagonist used in our research, Atopaxar, is pres-
ently in human trials for primary prevention of heart at-
tacks and strokes. Atopaxar crosses the blood-brain
barrier making it an appropriate medication to consider
for neuroprotection [42]. Thus, the use of PAR antago-
nists such as Atopaxar to prevent neurodegeneration is
a credible and unexploited use for this unique class of
medications [12].
PAR1 antagonism is only one component of the patho-
logical process we investigated. Studies have shown that
higher IL-1β levels in CSF are correlated with progres-
sion of clinical disability [43] in MS as well as with MS-
related cortical pathology on brain imaging [22]. IL-1β
in CSF enhances synaptic excitability [31] which may
contribute independently to neuronal dysfunction in the
brains of patients with MS. An IL-1 receptor antagonist
(anakinra) is an approved therapy for rheumatoid arth-
ritis; therapeutic anakinra levels can be achieved in hu-
man CSF [44]. The concentration of endogenous IL-1
receptor antagonists correlates with MS exacerbations in
several studies [45, 46]. Medications that antagonize IL-
1 receptors therefore have potential as disease-modifying
agents in MS both as a means of making relapses less
likely and for preventing transition from relapsing-
remitting to a progressive form of disease.
Given the failure of single-agent therapies to achieve
significant neuroprotection in numerous clinical trials,
proposing the concurrent use of two different agents,
one to inhibit PAR1 and another to prevent IL-1 recep-
tor signaling, reflects a realization of the complexity of
pathology in MS and that promoting effective neuropro-
tection may require manipulations of multiple pathways.
Combination therapy using two agents with differing
mechanisms at low doses might ameliorate the potential
toxicity of a single agent at a higher dose. Finally, it will
be desirable in heterogeneous diseases like MS to have
several options to address pathological processes whose
relative predominance may vary between patients with
the same diagnosis.
The described studies have limitations. The IL-1β and
granzyme B concentrations we detected in the CSF of
patients with progressive MS were within the ranges
noted by others who have investigated CSF samples
from patients with MS [18]. It would be expected that
using these methods with CSF samples from patients di-
agnosed with the most common presentation of MS,
relapsing-remitting, would replicate and expand our
neurotoxicity findings.
While the combination of granzyme B and IL-1β dem-
onstrated considerable toxicity in vitro, there are cer-
tainly many other potential factors that could impact
neurotoxicity in vivo. Our work and that of others [47]
suggests that IL-1β augments other toxins’ potencies,
Fig. 8 Effect of other second messengers on neurotoxicity.
a Pre-treatment with four different inhibitors (Ro 32–0432 hydrochloride,
LY 294002, FR 180204, Src Inhibitor-1) directed selectively against second
messengers (protein kinase C, PI3, ERK, and src kinase, respectively) all
of which activated by PAR1 failed to achieve significant reduction in
cumulative toxicity after 3 days of repeated exposure to granzyme B
and IL-1β. *p< 0.05, ****p< 0.0001 relative to control media, ##p< 0.01,
####p< 0.0001 relative to granzyme B+ IL-1β condition, repeated
measures ANOVA with post hoc Tukey’s test, n = 6 per condition. Data
are shown as the mean ± standard error of the mean from four separate
experiments. b 100 μM Minocycline produced a modest reduction
(<20%) in IL-1β augmented granzyme B neurotoxicity. #p< 0.05 relative
to granzyme B+ IL-1β condition, repeated measures ANOVA with post
hoc Tukey’s test, n = 5 per condition. Data are shown as the mean ±
standard error of the mean from four separate experiments
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but our findings do not infringe on the certainty that
there are other primary and secondary agents (both cel-
lular and soluble) that contribute to the complex path-
ology of MS.
Though there is a published correlation between IL-1β
in CSF and brain atrophy [22], no published studies have
correlated granzyme B levels with clinical or radio-
graphic measures of pathology in progressive forms of
MS. Because of the anonymity of the donated human
samples, we were unable to correlate the in vitro find-
ings with any clinical parameters. Future investigations
should attempt to correlate brain volumetric measure-
ments with CSF levels of granzyme B together with IL-
1β in the same patients longitudinally to see if high
levels of these inflammatory entities are as synergistic in
vivo as they appear to be in vitro. It would be worth-
while to see if clinical correlations exist between clinical
parameters such as cognitive assessments or fatigue rat-
ings and CSF granzyme B or IL-1β levels.
Since these studies were done in single-cell cultures,
this model is not a true replication of the central ner-
vous system environment which features multiple coex-
isting neuronal and glial cell populations. Investigators
have shown widespread PAR1 expression in several cell
types within the brain [8, 13, 15], and there is evidence
that granzyme B and IL-1β are each independently toxic
to glia [47, 48]. Future investigations should examine
whether these inflammatory mediators together might
provide another mechanism for glial or endothelial tox-
icity in MS. Brain atrophy related to MS might occur in-
directly through accelerated glial loss or enhanced
neurotoxicity through disruption of the neuronal
microenvironment.
The mechanism of how IL-1β upregulates PAR1 was
not definitively shown in this research. While the IL-1
receptor signals through protein kinase C, we did not
see any change in IL-1β toxicity with two different pro-
tein kinase C inhibitors. Since direct antagonism of the
IL-1 receptor fully inhibited the IL-1β effect, we do not
believe that the observed toxicity increase is receptor in-
dependent and speculate that another entity linked to
the IL-1 receptor such as calmodulin or NF-κB might be
potential mediators of the effect.
The use of E. coli-derived products is a potential con-
cern because recombinant products produced in other
species have glycosylation that differs from native hu-
man substances and potentially different effects than
their human analogues. However, the total replication of
the recombinant products’ in vitro neurotoxicity using
human CSF, and the correlation between CSF levels of
granzyme B and IL-1β in this research suggests that the
recombinant products were adequate to demonstrate the
same effects as human-derived compounds. While this
research used a pure population of human neurons
(predominantly glutamatergic and GABAergic), this is a
novel strength of this work since other publications have
used rodent (not human) neurons as targets for human-
derived reagents.
While our preparation was specifically designed to ex-
clude immune cells from the experiment and isolate any
findings to just soluble factors, we acknowledge that an
extensive literature exists concerning the roles of lym-
phocytes such as activated T cells and natural killer cells,
the sources of granzyme B and IL-1β, respectively, in the
pathology of progressive MS [49, 50]. Certainly, lympho-
cyte activation precedes granzyme B and IL-1β effects,
but our research supports the conclusion that ongoing
exposure to these two soluble immune factors is suffi-
cient to create an adverse environment for neurons ex-
posed to inflammatory CSF.
Conclusions
Our findings elucidate a novel mechanism for how
chronic exposure to IL-1β increases neuronal vulnerabil-
ity to granzyme B toxicity through activation of PAR1.
Despite having plausible roles in central nervous system
inflammation, these moieties and their downstream ef-
fectors have not been targeted specifically by current
therapeutic strategies used in the treatment of neuroin-
flammatory diseases. It is our hope that this report will
spur investigation into possible interventions for brain
volume loss which has proven to date to be an intract-
able process in neuroinflammatory diseases.
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